advertisement
Abstract #94894 Published in IGR 22-2
Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
Fridman G; Sadlak N; Sadlak N; Eliassi-Rad B; Desai MAJournal of Ocular Pharmacology and Therapeutics 2021; 37: 338-342
To analyze the efficacy, safety, and accessibility of netarsudil 0.02% in patients with glaucoma (suspect, open or closed) at a safety-net academic medical center, Boston Medical Center (BMC). Retrospective chart review of patients prescribed netarsudil 0.02% for uncontrolled glaucoma at BMC between December 2017 and September 2019. Outcome measures included change in intraocular pressure (IOP) from baseline and evaluation of adverse events (AEs). One hundred thirty patients (60% severe stage) were analyzed. The IOP reduction from baseline was about 3 mmHg. Fifty-four patients (42%) experienced an AE (eg, conjunctival hyperemia). Thirty-eight patients (29%) started netarsudil 0.02% in lieu of laser or surgery. Ninety-nine patients (71%) required prior authorization for insurance coverage of netarsudil 0.02%. Ten patients (7%) were unable to obtain netarsudil 0.02% due to issues with insurance coverage. Netarsudil 0.02% yielded significant IOP reduction in our cohort, however, to a smaller degree compared with prior studies that bore equivocal IOP reduction regardless of baseline IOP. Conjunctival hyperemia was the most common AE. In a limited number of patients, netarsudil 0.02% was not covered by insurance.
Department of Ophthalmology, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts, USA.
Full articleClassification:
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)